Evofem Biosciences AI Stock Analysis
Want to see EVFM full AI Analyst Report?
Evofem Biosciences (EVFM) AI Stock Analysis
Evofem Biosciences
(Other OTC:EVFM)
The score is driven down primarily by weak financial performance—shrinking TTM revenue, deeply negative profitability, ongoing negative cash flow, and a highly stressed balance sheet with negative equity and meaningful debt. A positive manufacturing expansion event provides some operational upside, but valuation is constrained by negative earnings and technical signals are largely unavailable, limiting support for a higher score.
Evofem Biosciences (EVFM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $801.81K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 0.32
- Revenue Growth
- -0.03%
- EPS Growth
- -88.76%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Evofem Biosciences Business Overview & Revenue Model
Company Description
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phex...
Evofem Biosciences Financial Statement Overview
Summary
Financials are very weak overall: TTM revenue declined sharply (-27.4%), profitability deteriorated to deeply negative (near -98% net margin), and operating/free cash flow remain negative. The balance sheet is the largest risk with persistent negative equity (TTM about -$78.8M) and sizable debt (about $70.4M) versus a very small asset base, implying elevated financing/dilution risk despite relatively strong gross margins (~69%).
Income Statement
34NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.72M | 20.18M | 19.36M | 18.22M | 16.84M | 8.24M |
| Gross Profit | 12.94M | 15.07M | 15.53M | 11.71M | 12.42M | 4.19M |
| EBITDA | -2.66M | 2.06M | -6.92M | -16.07M | -82.08M | -165.78M |
| Net Income | -12.73M | 391.00K | -8.86M | 52.98M | -76.70M | -205.19M |
Balance Sheet | ||||||
| Total Assets | 7.26M | 20.27M | 23.79M | 10.55M | 25.16M | 42.51M |
| Cash, Cash Equivalents and Short-Term Investments | 317.00K | 578.00K | 741.00K | 580.00K | 2.77M | 7.73M |
| Total Debt | 70.39M | 54.55M | 45.97M | 43.37M | 71.13M | 115.68M |
| Total Liabilities | 86.02M | 89.71M | 95.05M | 77.06M | 96.96M | 142.09M |
| Stockholders Equity | -78.76M | -69.44M | -71.26M | -66.51M | -71.80M | -99.58M |
Cash Flow | ||||||
| Free Cash Flow | -599.00K | -2.00M | -3.90M | -8.97M | -70.75M | -149.61M |
| Operating Cash Flow | -594.00K | -1.99M | -3.88M | -8.97M | -70.41M | -146.67M |
| Investing Cash Flow | -5,000 | -62.00K | -569.00K | -4,000 | -341.00K | -2.69M |
| Financing Cash Flow | 76.00K | 1.89M | 4.62M | 4.78M | 61.94M | 90.69M |
Evofem Biosciences Risk Analysis
Evofem Biosciences disclosed 87 risk factors in its most recent earnings report. Evofem Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksEvofem Biosciences Peers Comparison
Overall Rating
PTN46Neutral
LPCN45Neutral
EVFM43Neutral
DARE38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $10.91M | -1.15 | -115.00% | ― | -46.89% | 55.46% | |
| 45Neutral | $18.38M | -1.24 | -46.52% | ― | -13.37% | -33.44% | |
| 43Neutral | $801.81K | -0.06 | 16.78% | ― | -0.03% | -88.76% | |
| 38Underperform | $11.49M | -0.77 | -748.08% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EVFM | Evofem Biosciences, Inc. | 0.01 | 0.00 | 0.00% | |
| PTN | Palatin Technologies, Inc. | 6.13 | -7.68 | -55.62% | |
| DARE | Daré Bioscience | 0.58 | -1.13 | -65.85% | |
| LPCN | Lipocine Inc | 1.66 | -1.55 | -48.29% |
Evofem Biosciences Corporate Events
Evofem amends key convertible note financing terms
NeutralOn October 9, 2026, Evofem Biosciences, Inc. and Adjuvant Global Health Technology Fund entered into a fifth amendment to their October 14, 2020 Securities Purchase Agreement governing certain convertible promissory notes. The amendment extends and c...
Evofem Expands PHEXX Manufacturing Capacity for Global Growth
PositiveOn September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou to add them as a producer and supplier of PHEXX, its hormone-free contraceptive gel. The mov...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
